Inspyr Therapeutics, Inc. (NSPX)
|Net Income (ttm)||-291,000|
|Trading Day||January 26|
|Day's Range||0.0085 - 0.0098|
|52-Week Range||0.0005 - 0.7|
Proceeds support the development of lead asset, RT-AR001, an adenosine receptor antagonist Funds were secured from an existing institutional investor WESTLAKE VILLAGE, CA / ACCESSWIRE / Januar...
Inspyr Therapeutics, clinical-stage pharmaceutical company, focuses on the development of therapeutics for the treatment of diseases. It focuses on a pipeline of small molecule adenosine receptor modulators, such as A2B antagonists, dual A2A/A2B antagonists, and A2A agonists. The company was formerly known as GenSpera Inc. and changed its name to Inspyr Therapeutics, Inc. in August 2016. Inspyr Therapeutics, Inc. was founded in 2003 and is based in Westlake Village, California.
|Stock Exchange |
|Ticker Symbol |